Janux director granted RSUs and stock options

Janux Therapeutics director Ronald W. Barrett received new equity awards.

Rhea-AI Filing Summary

Janux Therapeutics director Ronald W. Barrett received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 11,750 shares. He also received a stock option for 15,500 shares at an exercise price of $13.66 per share, expiring on June 10, 2036.

The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continuous service. The option vests in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual stockholder meeting, also contingent on continued service.

Insider Trade Summary

Grant/Award: 21,000 shares

Grant/Award 2 txns

Insider Barrett Ronald W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	15,500	$0.00	$0.00
Grant/Award	Common Stock	5,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 15,500 contracts (Direct); Common Stock — 11,750 shares (Direct)

Footnotes (2)

1. F1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
2. F2. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Key Figures

RSU grant: 5,500 shares Option grant size: 15,500 shares Option exercise price: $13.66 per share +2 more

5 metrics

RSU grant 5,500 shares Restricted stock units granted on June 11, 2026

Option grant size 15,500 shares Stock option (right to buy) granted on June 11, 2026

Option exercise price $13.66 per share Exercise price for 15,500-share stock option

Option expiration June 10, 2036 Expiration date of stock option grant

Common shares after grant 11,750 shares Total common stock held directly after RSU award

Key Terms

restricted stock units ("RSUs"), Stock Option (right to buy), continuous service, annual meeting of the Issuer's stockholders

4 terms

restricted stock units ("RSUs") financial

"Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of $13.6600 per share..."

continuous service financial

"subject to the Reporting Person's continuous service on such date."

annual meeting of the Issuer's stockholders financial

"the date of the next annual meeting of the Issuer's stockholders..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Janux Therapeutics (JANX) report for Ronald W. Barrett?

Janux Therapeutics reported that director Ronald W. Barrett received 5,500 restricted stock units and a stock option for 15,500 shares. Both awards are compensation grants, not open-market purchases or sales, and are subject to future vesting based on his continued service.

How many Janux Therapeutics (JANX) shares does Ronald W. Barrett hold after this Form 4?

After the equity awards, Ronald W. Barrett directly holds 11,750 shares of Janux common stock and a stock option covering 15,500 shares. These figures reflect his position reported in the filing following the June 11, 2026 grant transactions.

What are the vesting terms for the 5,500 RSUs granted by Janux Therapeutics (JANX)?

The 5,500 RSUs vest on the earlier of June 11, 2027 or the date of Janux’s next annual stockholder meeting. Vesting is conditioned on Ronald W. Barrett’s continuous service with the company through the applicable vesting date.

What are the key terms of Ronald W. Barrett’s stock option grant at Janux Therapeutics (JANX)?

The stock option covers 15,500 shares of common stock at a $13.66 exercise price and expires June 10, 2036. It vests in equal monthly installments over 12 months after June 11, 2026, or is fully vested at the next annual meeting, subject to continued service.

Does the Janux Therapeutics (JANX) Form 4 show open-market buying or selling by Ronald W. Barrett?

The Form 4 shows compensation-related equity grants, not open-market buying or selling. Ronald W. Barrett acquired RSUs and an option at no cash cost per share, with future vesting conditions tied to his continued service as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barrett Ronald W

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		5,500(1)	A	$0	11,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.66	06/11/2026		A		15,500		(2)	06/10/2036	Common Stock	15,500	$0	15,500	D

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

2. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

	/s/ James Pennington, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)